Steroid trial for COVID brain fog halted early
NCT ID NCT05986422
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the steroid methylprednisolone could improve memory and thinking in people with long COVID. About 96 adults with ongoing memory problems were to receive either the drug or a placebo for six weeks. The trial was terminated early, so we don't know if the treatment works or is safe.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- methylprednisolone (a steroid that reduces inflammation)
- What this could lead to
- If it had worked, this could point toward a treatment for memory problems after COVID-19.
- What could go wrong
- The trial was terminated early, so we don't have clear results. Steroids like methylprednisolone can have side effects, and it's unknown if they help brain fog.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
96 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * History of confirmed (PCR or serology) SARS-CoV-2 infection according to WHO criteria * Ongoing symptoms of PCS for ≥ 3 months * Self-reported cognitive deficits at screening * Male or female adult who is 18 years or older at the time of informed consent * Subject is willing, understanding and able to provide informed consent * Signed informed consent prior to initiation of any trial related measure * For female subject or divers subjects: 1. Confirmed post-menopausal state, defined as amenorrhea for at least 12 months, or 2. If being of childbearing potential: 1. Negative highly sensitive urine or serum pregnancy test before inclusion, and 2. Practicing a highly effective birth control method (failure rate of less than 1%) Exclusion Criteria: * Any ongoing central nervous system disease * Any major psychiatric disease within the last 10 years * Previous medical history of gastric ulcer, osteoporosis and/or previous vertebral fractures, rheumatological disease or metabolic disease including diabetes mellitus * Ongoing immunosuppressive therapy * Patient is pregnant or breastfeeding at screening * MMQ memory satisfaction subdomain \>50 points at Screening * Current malignant disease (including space-occupying brain tumors) * Body weight \<45kg * Severe lactose intolerance * Participation in another clinical interventional trial within the last 3 months or five half- lives of the other trial's IMP, if longer than 6 months previous to informed consent * Patient is institutionalized by order of court or public authority * Patient who might be dependent on the sponsor, the investigator or the trial site * Place of living does not allow the subject to attend the planned study visits * Other conditions that are likely to affect to safety of the study treatment (e.g., severely impaired immune status)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Post-COVID-19 syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ear-Zapping device may help long COVID patients recover energy
- Will a digital boost keep Post-COVID recovery on track?
- Can tape or therapy soothe Post-COVID back pain?
- Brain fog after COVID: can two common drugs clear it?
- GP training may ease long COVID burden
- MRI study seeks clues to COVID brain fog